22 results on '"Wusheng Lu"'
Search Results
2. Preparation of Let-7b Nanocomposite and Its Effect on the Level of Inflammatory Factors in Cerebrospinal Fluid of Purulent Meningitis
- Author
-
Conghui Shi, Xinyu Wu, Yigang Yu, Wusheng Lu, Wenge Fang, Qingyin Shen, and Guixi Chen
- Subjects
General Materials Science - Abstract
This study was to explore the effect and mechanism of Let-7b nanocomposite on the expression of inflammatory factors in the cerebrospinal fluid (CSF) of purulent meningitis. 45 patients with purulent meningitis (PM) were selected as observation group (group A), and 38 patients with normal CSF without central nervous system diseases were selected as the control group (group B). The CSF of the two groups were collected to detect the inflammatory factors interleukin-8 (IL-8), macrophage inflammatory protein-1α (MIP-1α), matrix metalloproteinase 9 (MMP9), interleukin 1β (IL-1β), tumor necrosis factor-α (TNF-α), and Let-7b level with the double antibody sandwich enzyme-linked immunosorbent assay (ELISA). The Let-7b nanocomposite was prepared, and its morphology, particle size, and Zeta potential were analyzed. In addition, the degradation kinetics, cytotoxicity, and phagocytic efficiency (PE) of Let-7b nanocapsules were detected. 36 healthy adult New Zealand (NZL) rabbits were randomly grouped into a control group (group C) (0.9% normal saline (NS)), a model group (Escherichia coli (E. coli) modeling, group D), and a test group (E. coli modeling + Let-7b nanocapsules, group E), with 12 rabbits in each group. The changes of inflammatory factors in CSF of the three groups were detected and compared. It was found that the expression levels of IL-8 and IL-1 β in the group A were much higher than those in the group B (P < 0.01), and the MMP9 and TNF-α levels in the group B were much lower in contrast to the group A (P < 0.001). The expression of Let-7b in the group A was lower obviously in contrast to the group B (P < 0.001). Let-7b nanocapsules were irregularly spherical, with an average particle size (APS) of 23.1 nm, a polydispersity index (PDI) of 0.232, and the Zeta potential of around +15 mV. Let-7b nanocapsules showed obvious polymer shell absorption peaks at 1,015 cm-1, 1,228 cm-1, and 1,547 cm-1. The IL-8 and IL-1β levels of the group D were greatly different from those in the other two groups (P < 0.01). The levels of TNF-α and MMP9 in the group D were greatly different in contrast to the group C (P < 0.001) and the group E (P < 0.01). It indicated that Let-7b nanocomposite could lower the expression levels of IL-8, IL-1β, MMP9, and TNF-α in the CSF of patients with purulent meningitis dramatically, which provides a reliable basis for immunotherapy of purulent meningitis with Let-7b.
- Published
- 2021
3. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma
- Author
-
Wei Peng, Xiaoyun Zhang, Chuan Li, Xinrui Zhu, Qiu Li, Weixia Chen, Wusheng Lu, Chang Liu, Yongjie Zhou, Yujun Shi, Tianfu Wen, and Xin Sun
- Subjects
Surgery - Abstract
The IDEAL framework allowed safe introduction of salvage liver resection after LEN-TAP strategy in an evidence-based manner without exposing the initial patients to unacceptable risk. The findings showed that LEN-TAP conversion strategy is feasible with manageable AEs for uHCC, and salvage liver resection is safe and beneficial.
- Published
- 2022
4. CONVERSION RATE CONTROL OF TiCl4 HYDROLYSIS TO PREPARE NANO TiO2
- Author
-
Qianjun Le, Shengfei Yu, and Wusheng Luo
- Subjects
TiCl4 ,hydrolysis ,TiO2 ,reaction kinetics ,Chemistry ,QD1-999 - Abstract
In the water/triethanolamine/ethanol system, TiCl4 aqueous solution is used as the precursor to regulate the conversion rate of TiCl4 by changing the reaction temperature, water volume, pH value, and ethanol amount. The experiment uses a single-factor method to investigate the dynamic relationship between Ti4+ concentration and time under various factors, thereby achieving controllable TiO2 production. The experimental results showed that under a single factor, the conversion rate showed a trend of first steep and then slow growth within 180 min. After 180 min, the conversion rate tended to stabilize. Considering various factors, it was found that VTiCl4:VC6H15NO3:VH2O:VC2H5OH = 1:6:15:30, pH = 7, reaction time at room temperature was 4 h, and the hydrolysis effect was good. The final conversion rate was 90.46%, and the hydrolysis reaction conforms to the first-order reaction equation. Kinetic parameters: pre-factor (A) = 0.107, activation energy (Ea) = 4488.65 J mol-1.
- Published
- 2024
- Full Text
- View/download PDF
5. Programmed cell death protein 1 and tyrosine kinase inhibition plus transcatheter arterial chemoembolization of advanced hepatocellular carcinoma.
- Author
-
Wei Peng, Xiaoyun Zhang, Chuan Li, Xinrui Zhu, Qiu Li, Weixia Chen, Wusheng Lu, Chang Liu, Yongjie Zhou, Yujun Shi, Tianfu Wen, and Xin Sun
- Subjects
CHEMOEMBOLIZATION ,HEPATOCELLULAR carcinoma ,RECEPTOR for advanced glycation end products (RAGE) - Published
- 2023
- Full Text
- View/download PDF
6. (131)Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment
- Author
-
Bo Li, Yu Ma, Wusheng Lu, Lin Li, Xiao-Li Chen, and Li-Geng Duan
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Therapeutic effect ,Gastroenterology ,medicine.disease ,Single Center ,Microsphere ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Gelatin microspheres ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Internal medicine ,medicine ,030211 gastroenterology & hepatology ,Doxorubicin ,Original Article ,Embolization ,Transcatheter arterial chemoembolization ,business ,medicine.drug - Abstract
BACKGROUND: To evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) with (131)iodine-doxorubicin-eluting gelatin microspheres ((131)I-DEM TACE) compared with conventional TACE (cTACE) with polyvinyl alcohol foam (PVA) embolization microspheres. METHODS: A total of 22 patients diagnosed with hepatocellular carcinoma were equally divided into 2 groups. The patients who underwent TACE with (131)I-DEM (25.7×10(7) Bq of 131iodine and 10 mg of doxorubicin) were compared to controls who received cTACE with PVA embolization microspheres. Therapeutic effects were evaluated by the tumor regression rates, levels of alpha-fetoprotein in serum, survival rates, and complications. RESULTS: The operative complications of the 2 groups were not significantly different (P=0.753). The radioactivity ratio of the tumor to the liver was approximately 4.1:1 for the (131)I-DEM TACE group. In the (131)I-DEM TACE group, 54.5% of patients achieved tumor regression of more than 50%, compared to 36.6% of patients in the cTACE group. AFP levels in serum declined in 100% of patients in the (131)I-DEM TACE group and 50% of patients in the cTACE group. The median survival time of the patients was 12.0±3.3 months for the (131)I-DEM TACE group and 10.0±3.3 months for the cTACE group. There were no significant differences in survival between the 2 groups (P=0.414). CONCLUSIONS: (131)I-DEM may become a potential radiochemoembolization agent to treat patients with unresectable hepatocellular carcinoma through TACE.
- Published
- 2021
7. The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma
- Author
-
Xiaoyun Zhang, Xinrui Zhu, Chang Liu, Wusheng Lu, Qiu Li, Weixia Chen, Zhiping Li, Qiang Lu, Wei Peng, Chuan Li, Lvnan Yan, Jiayin Yang, and Tianfu Wen
- Subjects
Cancer Research ,Oncology - Abstract
453 Background: More than 70% of hepatocellular carcinoma (HCC) patients are in the intermediate or advanced stages at the time of diagnosis. TACE, TKI and PD-1 antibody are all recommended for patients with unresectable HCC (uHCC) according to Chinese HCC guidelines. There are few scientific trials to back up the safety and effecacy of TACE+TKI+PD-1 antibody for the treatment of uHCC and conversion resection. In this study, we explored the safety and efficacy of the TACE+TKI+PD-1 antibody in uHCC. Methods: This is a prospective, multicenter, cohort study (NCT04997850). Key Eligibility Criteria:18 years old ≤ age ≤ 70 years old; HCC confirmed by histopathology or cytology; No systemic treatment history. ECOG PS score 0-1; Child-Pugh A/B; BCLC stage B/C.Experience group: TACE + Lenvatinib (12mg when≥ 60kg/8mg when < 60kg QD) + Camrelizumab/ Sintilimab (200 mg ivgtt Q3W);Control group: TACE. Results: From Sep 2020 to May 2021, 38 patients were enrolled in experimental group (Table). At the cutoff date (Sep 10 2021), the median follow-up was of 33.34 weeks (Table). The conversion resection rate was 50% (19/38), and the conversion success rate was 52.6% (20/38). Among the 19 patients, 5 cases achieved complete pathological response and 1 case achieved major pathological response. The 48 weeks’ OS rate and PFS were 96.4% (95%CI 92.9% to 99.9%) and 91.7%(95%CI 85.8% to 97.4%).22 patients had level 3 treatment related adverse events (TRAE), there were no level 4 and 5 TRAEs. At the last follow-up, the ORR rate based on mRECIST was 84.2%, and the DCR rate was 94.7% (Table). Conclusions: TACE + Lenvatinib + PD-1 antibody is safe and effective, and conversion resection after the triple-treatment is feasible for uHCC. Clinical trial information: 04997850.[Table: see text]
- Published
- 2022
8. Overexpression of MicroRNA-133a Inhibits Apoptosis and Autophagy in a Cell Model of Parkinson’s Disease by Downregulating Ras-Related C3 Botulinum Toxin Substrate 1 (RAC1)
- Author
-
Jinhuang Lin, Wusheng Lu, Chunyong Hong, Laishun Ke, Xinyu Wu, Dequan Zheng, and Peineng Chen
- Subjects
rac1 GTP-Binding Protein ,1-Methyl-4-phenylpyridinium ,Parkinson's disease ,RAC1 ,Apoptosis ,030204 cardiovascular system & hematology ,MicroRNAs Parkinson Disease ,PC12 Cells ,Receptor, IGF Type 1 ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,Lab/In Vitro Research ,microRNA ,medicine ,Autophagy ,Humans ,Animals ,Cell Proliferation ,Cell growth ,Chemistry ,Parkinson Disease ,General Medicine ,Cell cycle ,medicine.disease ,Rats ,MicroRNAs ,030220 oncology & carcinogenesis ,Cancer research - Abstract
BACKGROUND Parkinson's disease (PD) is a movement disorder. microRNA (miR)-133 expression is reduced in PD patients and in mice with a dopamine neuron deficiency. We aimed to identify the mechanism of miR-133a in apoptosis and autophagy in PD. MATERIAL AND METHODS The optimal concentration of MPP⁺ (1-methyl-4-phenylpyridinium ion) was initially determined to construct a PD cell model. Gain-of function experiments were carried out to evaluate the role of miR-133a in PD. The levels of miR-133a, RAC1 (Ras-related C3 botulinum toxin substrate 1), apoptosis-related factors, and autophagy-related factors were detected after detection of cell proliferation, cell cycle, and apoptosis. Transmission electron microscopy was applied to observe autophagosomes, and immunofluorescence staining was performed to detect LC3 and further analyze the effect of miR-133a on autophagy in a PD cell model. RESULTS Low miR-133a expression was detected in a cell model of MPP⁺-induced PD. After overexpressing miR-133a, cell proliferation increased, and apoptosis (cleaved caspase-3 and Bax levels decreased, while Bcl2 levels increased) and autophagy was inhibited (LC3II/I and Beclin-1 levels decreased, while p62 levels increased). MiR-133a targeted RAC1. RACY upregulation attenuated the inhibitory effects of miR-133a on PC12 cell apoptosis and autophagy. CONCLUSIONS Our data highlighted that miR-133a overexpression prevented apoptosis and autophagy in a cell model of MPP⁺-induced PD by inhibiting RAC1 expression.
- Published
- 2020
9. Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria
- Author
-
Bo Li, Jiayin Yang, Tianfu Wen, Lunan Yan, Ming-qing Xu, Xiaoyun Zhang, Li Jiang, Wentao Wang, Chuan Li, and Wusheng Lu
- Subjects
Adult ,Male ,Reoperation ,Curative resection ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Time Factors ,Kaplan-Meier Estimate ,Milan criteria ,Risk Assessment ,Decision Support Techniques ,Predictive Value of Tests ,Risk Factors ,medicine ,Carcinoma ,Hepatectomy ,Humans ,In patient ,Chemoembolization, Therapeutic ,Proportional Hazards Models ,Retrospective Studies ,Hepatology ,business.industry ,Liver Neoplasms ,Gastroenterology ,Retrospective cohort study ,Middle Aged ,medicine.disease ,digestive system diseases ,Surgery ,Treatment Outcome ,Predictive value of tests ,Hepatocellular carcinoma ,Catheter Ablation ,Treatment strategy ,Female ,Neoplasm Recurrence, Local ,business - Abstract
The aim of this study was to investigate appropriate treatment strategies for recurrent intrahepatic hepatocellular carcinoma (HCC) in patients who fulfilled the Milan criteria at primary hepatectomy.A total of 124 patients who underwent curative-intent resection of HCC at our center between January 2007 and March 2014 were retrospectively enrolled; patients had initially fulfilled the Milan criteria, but developed intrahepatic recurrence. Seventy-four patients underwent transarterial chemoembolization (TACE) and another 50 patients underwent repeat resection (RR) or radiofrequency ablation (RFA). The recurrent HCCs were classified into intrahepatic metastasis and multicentric occurrence by pathologic analysis. Demographic and clinical data and overall survival rates were compared between the RR/RFA and the TACE groups. Subgroup analysis on the basis of the recurrence pattern (early recurrence or late recurrence) was carried out, and prognostic factors for survival were investigated.The 1-, 3-, and 5-year overall survival rates for the 124 patients after retreatment were 88.3, 55.4, and 44.3%, respectively. The 1-, 3-, and 5-year overall survival rates after retreatment were not significantly different between the RR/RFA and the TACE groups (P=0.140). Subgroup analysis showed that for late recurrence, survival in the RR/RFA group was better than those of patients in the TACE group (P=0.045).TACE may be as effective as RR or RFA for early intrahepatic recurrence, whereas RR/RFA is the preferred option for patients with late recurrence after curative resection of HCC who initially fulfilled the Milan criteria. Prognosis was determined by the number of recurrent tumors and the Child-Pugh class at the time of recurrence.
- Published
- 2015
10. Overexpression of MicroRNA-133a Inhibits Apoptosis and Autophagy in a Cell Model of Parkinson's Disease by Downregulating Ras- Related C3 Botulinum Toxin Substrate 1 (RAC1).
- Author
-
Wusheng Lu, Jinhuang Lin, Dequan Zheng, Chunyong Hong, Laishun Ke, Xinyu Wu, and Peineng Chen
- Published
- 2020
- Full Text
- View/download PDF
11. Particle Formation Mechanism of TiCl4 Hydrolysis to Prepare Nano TiO2
- Author
-
Qianjun Le, Shengfei Yu, and Wusheng Luo
- Subjects
TiCl4 hydrolysis ,particle formation mechanism ,Aspen Plus chemical process simulation ,particle distribution ,Technology ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Biology (General) ,QH301-705.5 ,Physics ,QC1-999 ,Chemistry ,QD1-999 - Abstract
This study utilizes Aspen Plus chemical process simulation software (V11), applies uniform nucleation theory and growth kinetics equations, and explores the particle formation mechanism of TiCl4 hydrolysis to prepare nano TiO2. In the water/ethanol system, the effects of the reaction time, reaction temperature, water addition, pH value, and ethanol amount on the crystal nucleation rate and TiO2 particle distribution (PSD) were studied in detail by adding triethanolamine dropwise and using the Aspen Plus chemical process software simulation calculation method. The calculation results indicate that at room temperature, the formation of TiO2 crystal nuclei mainly occurs in the first 300 s and then enters the growth stage. The reaction was carried out under neutral conditions at room temperature for 4 h in 1 mL TiCl4, 6 mL C6H15NO3, 15 mL H2O, and 30 mL C2H5OH. The maximum number of particles reached 195 mesh per cubic micrometer, and the particle size after crystal nucleus growth was smaller, with a D50 of 6.15 nm. The distribution curve shows a normal distribution, which is basically consistent with the experimental results. When studying various factors, it was found that controlling the reaction time within 60 min and maintaining the reaction temperature at room temperature can reduce the particle size D50 to 2.44 nm. Continuing to adjust the amount of water added, it was found that at 1 mL, D50 decreased again to 0.19 nm. Adjusting the pH value found that maintaining the neutrality did not change the particle size. Continuing to adjust ethanol, it was found that adding an appropriate amount of ethanol promoted nucleation and growth. At 4 mL, the maximum number of particles reached 199 mesh per cubic micrometer, but D50 slightly increased to 0.24 nm.
- Published
- 2023
- Full Text
- View/download PDF
12. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical Phase I/II trials
- Author
-
Airong Qian, Yunchun Li, Xiang-Min Yang, Huijie Bian, Nan Leng, Fei Song, Qing Zhang, Guo-Hui Xu, Xiao-Ling Yu, Yu Li, Ping Zhu, Rong Tian, Peng Shang, Hongxin Zhang, De-Rong Liang, Sihe Zhang, Anren Kuang, Zhenbiao Wu, Jia Miao, Tingshu Mo, Zhi-Hui Zhang, Jinliang Xing, Li Mi, Qing-Guang Liu, Jian-Li Jiang, Han Jun, Zhi-Nan Chen, Yuan Feng, Jing Xu, Kejun Nan, Tianzhi Tan, Zheng Zhang, Qiang Feng, Ling Li, Xian-Hui Wang, and Wusheng Lu
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Adolescent ,Maximum Tolerated Dose ,medicine.medical_treatment ,Antineoplastic Agents ,Gastroenterology ,law.invention ,Iodine Radioisotopes ,Pharmacokinetics ,Randomized controlled trial ,law ,Internal medicine ,Carcinoma ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Survival rate ,Aged ,Radiation ,business.industry ,Liver Neoplasms ,Antibodies, Monoclonal ,Middle Aged ,Radioimmunotherapy ,medicine.disease ,Surgery ,Clinical trial ,Drug Combinations ,Oncology ,Hepatocellular carcinoma ,Basigin ,Female ,business ,Progressive disease - Abstract
Purpose: HAb18G/CD147 is a hepatocellular carcinoma (HCC)-associated antigen. We developed iodine ( 131 I) metuximab injection (Licartin), a novel 131 I-labeled HAb18G/CD147-specific monoclonal antibody F(ab') 2 fragment, and evaluated its safety, pharmacokinetics, and clinical efficacy on HCC in Phase I/II trials. Methods and Materials: In a Phase I trial, 28 patients were randomly assigned to receive the injection in 9.25-, 18.5-, 27.75-, or 37-MBq/kg doses by hepatic artery infusion. In a multicenter Phase II trial, 106 patients received the injection (27.75 MBq/kg) on Day 1 of a 28-day cycle. Response rate and survival rate were the endpoints. Results: No life-threatening toxic effects were found. The safe dosage was 27.75 MBq/kg. The blood clearance fitted a biphasic model, and its half-life was 90.56–63.93 h. In the Phase II trial, the injection was found to be targeted and concentrated to tumor tissues. Of the 73 patients completing two cycles, 6 (8.22%) had a partial response, 14 (19.18%) minor response, and 43 (58.90%) stable disease. The 21-month survival rate was 44.54%. The survival rate of progression-free patients was significantly higher than that of patients with progressive disease after either one or two cycles ( p p = 0.0019). Conclusion: Iodine ( 131 I) metuximab injection is safe and active for HCC patients.
- Published
- 2006
13. Biodistribution and localization of iodine-131 labeled metuximab in patients with hepatocellular carcinoma
- Author
-
Zhu Ping, Huijie Bian, Rong Tian, Li Mi, Zhinan Chen, Feng Qiang, Yunchun Li, Anren Kuang, Wusheng Lu, Yang Zhang, Tingshu Mo, Tianzhi Tan, Zheng Zhang, and Min Zhang
- Subjects
Adult ,Male ,Cancer Research ,Biodistribution ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Phytic Acid ,medicine.medical_treatment ,chemistry.chemical_element ,Single-photon emission computed tomography ,Iodine ,Iodine Radioisotopes ,medicine ,Carcinoma ,Humans ,Tissue Distribution ,In patient ,Aged ,Tomography, Emission-Computed, Single-Photon ,Pharmacology ,SPECT SCAN ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,Antibodies, Monoclonal ,Organotechnetium Compounds ,Middle Aged ,Radioimmunotherapy ,medicine.disease ,Oncology ,chemistry ,Hepatocellular carcinoma ,Molecular Medicine ,Female ,Radiology ,business ,Nuclear medicine - Abstract
Radioimmunotherapy may improve the outcome of hepatocellular carcinoma (HCC) patients by delivering targeted radiation to liver lesion tissue while relatively sparing nontarget tissues. This study was designed to observe the biodistribution, localization and imaging characteristics of 131I -labeled Metuximab in 24 patients with HCC to determine the diagnostic and therapeutic potential of this antibody.Twenty-four HCC patients were randomly divided into three groups to receive 18.5, 27.75 and 37 MBq/kg of 131I-labeled Metuximab per kilogram of body weight, respectively. 99mTc-sodium phytate was administered intravenously and the single photon emission computed tomography (SPECT) scanning was performed. After 48 h, 131I -labeled Metuximab was injected by hepatic artery intubation, and SPECT scan performed at 7 d. The percentage of absorbed 131I (%ID) and the time-dependent 131I tumor:nontumor tissue (T/NT) ratios were calculated at 12, 48, 96 and 192 h after injection.The positive Imaging result of MAb scanning in 24 patients showed that the iodine 131 conjugated to Metuximab was apparently accumulated more in hepatoma. Biodistribution studies of 131I-Metuximab in trial I demonstrated that the comparable % ID uptake in tumor (with a T/NT ratio at 12, 48, 96 and 192 h) to that in such normal organs, as thyroid, heart, lung, spleen and intestines were all more than one. The optimal imaging time for the highest T/NT ratio in liver was at 192 h.131I-labeled Metuximab could deliver relatively selective radiation to tumor tissues and may have potential efficacy in relieving hepatocellular carcinoma.
- Published
- 2006
14. Preoperative transarterial chemoembolization does not increase hepatic artery complications after liver transplantation: A single center 12-year experience
- Author
-
Wentao Wang, Jia-Yin Yang, Wusheng Lu, Bo Li, Tian-Fu Wen, Lvnan Yan, Hongyu Li, Yong-Gang Wei, and Ming-Qing Xu
- Subjects
Adult ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,medicine.medical_treatment ,Liver transplantation ,Single Center ,Preoperative care ,Hepatic Artery ,Postoperative Complications ,Preoperative Care ,medicine ,Carcinoma ,Edema ,Humans ,Chemoembolization, Therapeutic ,Retrospective Studies ,Antibiotics, Antineoplastic ,Hepatology ,business.industry ,Liver Neoplasms ,Gastroenterology ,Antibodies, Monoclonal ,Retrospective cohort study ,medicine.disease ,Thrombosis ,Neoadjuvant Therapy ,Surgery ,Liver Transplantation ,Doxorubicin ,Hepatocellular carcinoma ,Female ,Complication ,business - Abstract
Summary Background As a bridge to liver transplantation or downstaging therapy for hepatocellular carcinoma (HCC) patients, preoperative transarterial chemoembolization (TACE) has potential risks in causing damage to hepatic artery (HA), resulting in severe postoperative complications. Aim To evaluate the impact of pre-TACE on postoperative hepatic artery complications (HAC) for HCC patients in a single liver transplant center. Materials and methods Clinical data of 450 HCC patients undergoing orthotopic liver transplantation (OLT) from January 2001 to December 2013 were retrospectively analyzed. Patients were divided into Group 1 (with pre-TACE) and Group 2 (without pre-TACE). Preoperative characteristics and postoperative HAC were compared. Results One hundred and eleven patients (69 men; median age, 37 ± 9.9 years) in Group 1 were compared with 339 patients (244 men; median age, 38.8 ± 8.0 years) in Group 2. Patients were comparable in donor/recipients characteristics between groups. Histological review for native liver samples showed that Edema was the most often seen complication following pre-OLT TACE (troncluar: 87 vs 9; segmental: 91 vs 10; liver parenchyma: 93 vs 8; P = 0.000). Fibrosis, thrombosis and aneurysm were only seen in Group 1. There were no significant difference in postoperative HAC (5/111 (4.5%) vs 5/339 (1.5%), P = 0.131) between groups. Conclusion Our single institution experience showed that it might be safe to perform pre-TACE in HCC patients before OLT. It would not increase postoperative HAC risk.
- Published
- 2014
15. [Surgical strategy in treatment of diabetic foot]
- Author
-
Shiqiang, Cen, Fuguo, Huang, Jichun, Zhao, Wusheng, Lu, Chun, Wang, and Xingwu, Ran
- Subjects
Adult ,Aged, 80 and over ,Gangrene ,Male ,Wound Healing ,Humans ,Female ,Middle Aged ,Foot Ulcer ,Diabetic Foot ,Aged ,Follow-Up Studies - Abstract
To investigate the surgical strategy of diabetic foot (DF) and analyze the therapeutic efficacy.From July 2004 to July 2007, 36 patients (22 males and 14 females) with DF were treated, with an average age of 57 years(43-82 years). The disease course of diabetes was 3 months to 27 years (12 years on average) and the disease course of DF was 1 month to 2 years (7 months on average). According to Wagner classification of DF, there were 3 cases of grade 1, 12 cases of grade 2, 10 cases of grade 3, 7 cases of grade 4 and 4 cases of grade 5. The locations of ulcer were ankle and heel in 9 cases, medial part of foot in 14 cases, in lateral part of foot in 8 cases and sinus formation in 5 cases. The ulcer sizes ranged from 4 cm x 2 cm-18 cm x 9 cm. Initial management of these patients included control of blood sugar level, proper hydration, administration of antibiotics, treatment of coexisting diseases, and repeated debridements of wounds when necessary. Ulcers were treated with debridement and split skin transplantation in 3 cases of grade 1, with debridement and drainage of abscesses and split skin transplantation in 12 of grade 2, with debridement and transplantation of flap in 17 of grade 3 and grade 4, and with transplantation of fascial flap in 5 cases of sinus; ulcers were treated firstly with artery bypass of lower extremity, and then treated with local amputation of foot to avoid high-level amputation and to save more function of foot in 4 of grade 5.In 36 cases, wound in 31 cases (86.1%) cured primarily, wound did not heal in 1 patient (2.1%) and received re-amputation, there were 2 deaths because of infection with multiple organ failure postoperatively. Twenty-nine cases were followed up 8 months (range, 6 -15 months). Eight patients developed new ulcers, with 3 lesions in situ and 5 lesions in new site.Surgical regimen could play an important role in treatment of diabetic foot. According to different grades of DF, there were different strategies in dealing with the accompanied inflammation and ulcer. An active and comprehensive surgical treatment of DF could save the foot, avoid the high-level amputation and result in more functional extremity.
- Published
- 2008
16. [Pharmacokinetics of injection of iodine-131 labelling MEI-TUO-XI monoclonal antibody in human body]
- Author
-
Yunchun, Li, Tianzhi, Tan, Tingshu, Mo, Wusheng, Lu, Houfu, Deng, Xiaochuan, Yang, and Xiao, Li
- Subjects
Adult ,Male ,Adolescent ,Antibodies, Neoplasm ,Liver Neoplasms ,Antibodies, Monoclonal ,Middle Aged ,Radioimmunotherapy ,Iodine Radioisotopes ,Immunoglobulin Fab Fragments ,Young Adult ,Drug Delivery Systems ,Hepatic Artery ,Injections, Intra-Arterial ,Humans ,Female ,Aged - Abstract
To study pharmacokinetics of injection of iodine-131 labelling MEI-TUO-XI monoclonal antibody (hepatoma monoclonal antibody HAb18 F(ab')2) in vivo. 24 cases of primary hepatocelluar carcinoma (PHC) were equally divided into the low dose group, middle dose group and high dose group. After the relevant injection was administrated into the hepatic artery of each case, intravenous blood and urine samples were separately collected at different time for determination of the radioactive count ratio (min(-1)). The proportion of 131I-HAb18 F(ab')2 in serum of each blood sample was determined, and the radioactive count ratio (min(-1)) of druggery for each blood sample was revised according to the proportion. The pharmacokinetic parameters were calculated using DAS ver 1.0 (Drug And Statistics for Windows) program. The component of urine radiomaterial was determined and the percentages of urine radioactivity in administration dosage were calculated. The catabolism of the injection with time accorded with dynamics two-compartment model. The catabolism product was mainly free-131I and was excreted via kidney; the urine radioactivity was 47.70%-51.16% of administration dosage during 120 h after administration of drug. Therefore, the pharmacokinetics of the injection can satisfy the clinical demands. The drug dose recommended for clinical use was 27.75 MBq of the injection for each kg of human body.
- Published
- 2007
17. [Biological distribution of 131I-HAb18F(ab')2 in patients with hepatocellular carcinoma]
- Author
-
Wusheng, Lu, Xiao, Li, Chaohua, Wang, Wenxiu, Liu, He, Jiao, Tingshu, Mo, and Zhinan, Chen
- Subjects
Adult ,Male ,Carcinoma, Hepatocellular ,Liver Neoplasms ,Antibodies, Monoclonal ,Middle Aged ,Radioimmunotherapy ,Iodine Radioisotopes ,Immunoglobulin Fab Fragments ,Humans ,Female ,Tissue Distribution ,Radiopharmaceuticals ,Aged - Abstract
Before 131I-HAb18F(ab')2 administration, 24 cases of mid-term or advanced hepatocellular carcinoma(HCC) were given Lugol's Liquid to block the thyroid gland, and submitted to hepatic colloid imaging. The cases were randomly divided into 3 groups. Then 131I-HAb18F(ab')2 was injected into the target hepatic artery with doses of 0.5, 0.75, 1.0 mCi/kg, respectively. At the followed 10, 48, 96 and 192 hours, 131I-HAb18F(ab')2 distribution in human body was acquired by whole body dynamic image with Single photon emission computed tomography(SPECT). The results showsed that 131I-HAb18F(ab')2 in tumor tissue was significantly higher than that in normal liver tissue and other organs. This difference became obvious as time passed. 131I-HAb18F(ab')2 is stable in human body and it can combine with HCC tissue specifically. So it is a new medicine deserving further research for the treatment of HCC.
- Published
- 2004
18. Successful Treatment With Selective and Transplenic Artery Embolization for Small-for-Size Syndrome: A Case Report
- Author
-
Zheyu Chen, Qiang Lu, Wentao Wang, Wusheng Lu, Jia-Yin Yang, Tianfu Wen, Weixia Cheng, Ming-Qing Xu, and Lunan Yan
- Subjects
Transplantation ,Small for size syndrome ,medicine.medical_specialty ,business.industry ,Artery embolization ,Medicine ,Radiology ,business - Published
- 2007
19. O-149 A randomized clinical trial of preoperative neoadjuvant chemotherapy followed by surgery in the treatment of stage III non-small cell lung cancer
- Author
-
Youlin Gong, Jianjun Qin, Mei Hou, Zhiping Li, Junjie Yang, Jun Chen, Guowei Che, Yun Wang, Wusheng Lu, Lunxu Liu, Quinghua Zhou, Lu Li, and Yongfan Zhao
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Stage III Non-Small Cell Lung Cancer ,Surgery ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,medicine ,business - Published
- 2003
20. Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern.
- Author
-
Xiaoyun Zhang, Chuan Li, Tianfu Wen, Lunan Yan, Bo Li, Jiayin Yang, Wentao Wang, Mingqing Xu, Wusheng Lu, and Li Jiang
- Published
- 2015
- Full Text
- View/download PDF
21. Distributed Collaborative Camera Actuation Scheme Based on Sensing-Region Management for Wireless Multimedia Sensor Networks
- Author
-
Wusheng Luo, Qin Lu, and Jingjing Xiao
- Subjects
Electronic computers. Computer science ,QA75.5-76.95 - Abstract
Considering the high energy consumption of image acquisition, computation, and transmission in wireless multimedia sensor networks (WMSNs), two-tier network structure is usually used to lighten the energy consumption burden on camera sensors. Thus, a camera sensor can only be actuated when an event is detected by scalar sensors within its field of view (FoV). In this paper, we study the event-driven camera actuation problem and propose a distributed collaborative camera actuation scheme based on sensing-region management (DCCA-SM). The basic idea of this scheme is to divide the whole sensing field into many sensing regions which are covered by different sets of camera sensors. During the running of the network, by forming a cluster of the scalar sensors in each sensing region, the events occurring in each sensing region can be managed by the scalar cluster head. Therefore, by hearing from the scalar cluster heads, each camera sensor can know the exact coverage overlaps without changing information with the neighboring camera sensors. Meanwhile, sensing-region management avoids repeatedly event reporting from scalar sensors. In order to show the performance of the DCCA-SM, a simulation has been conducted. The comparative performance evaluations demonstrate effectiveness and energy efficiency of the proposed scheme.
- Published
- 2012
- Full Text
- View/download PDF
22. Elongin B is a binding partner of the male germ cell nuclear speckle protein sperm-associated antigen 16S (SPAG16S) and is regulated post-transcriptionally in the testis.
- Author
-
Zhang Z, Huang Q, Wang Z, Zou J, Yu Z, Strauss Iii JF, and Zhang Z
- Subjects
- Animals, Gene Expression Regulation, Male, Mice, Spermatozoa metabolism, Transcription, Genetic, Elongin metabolism, Spermatogenesis physiology, Testis metabolism
- Abstract
In this study we identified Elongin B, a regulatory subunit of the trimeric elongation factor Elongin ABC, which increases the overall rate of elongation by RNA polymerase II, as a major binding partner of sperm-associated antigen 16S (SPAG16S), a component of nuclear speckles. Nuclear speckles are nuclear subcompartments involved in RNA maturation. Previously, we showed that SPAG16S is essential for spermatogenesis. In the present study, a specific antibody against mouse Elongin B was generated and reacted with a protein with the predicted size of Elongin B in the testis; immunofluorescence staining revealed that the Elongin B was located in the nuclei and residual bodies. In round spermatids, Elongin B was colocalised with splicing factor SC35 (SC35), a marker of nuclear speckles. During the first wave of spermatogenesis, Elongin B transcripts were initially detected at Postnatal Day (PND) 8, and levels were greatly increased afterwards. However, Elongin B protein was only found from PND30, when germ cells progressed through spermiogenesis. Polysomal gradient analysis of Elongin B transcripts isolated from adult mouse testes revealed that most of the Elongin B mRNA was associated with translationally inactive, non-polysomal ribonucleoproteins. An RNA electrophoretic mobility shift assay demonstrated that the 3' untranslated region of the Elongin B transcript was bound by proteins present in testis but not liver extracts. These findings suggest that post-transcriptional regulation of Elongin B occurs in the testis, which is a common phenomenon during male germ cell development. As a major binding partner of SPAG16S, Elongin B may play an important role in spermatogenesis by modulating RNA maturation.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.